Connect with us

Cannabis News

Safe Harbor Financial expands Board of Directors with Tyler Klimas and Sean Tonner

Published

2 weeks ago

on

Safe Harbor Financial has appointed Tyler Klimas and Sean Tonner to its Board of Directors (“Board”) effective April 22, 2026. The appointments expand the Board from five to six members. Mr. Klimas has been appointed to the Audit Committee, the Compensation Committee and the Nominating and Corporate Governance Committee, and will be the Chairman of the Nominating and Corporate Governance Committee. Mr. Tonner has been appointed to the Compensation Committee and the Nominating and Corporate Governance Committee, and will serve as Chairman of the Compensation Committee.

The Company also notes that Richard Carleton has previously notified the Board that he will not seek re-election at the Company’s 2026 annual meeting of stockholders (the “Annual Meeting”). Mr. Carleton’s decision is not the result of any disagreement with the Company on any matter related to its operations, policies or practices. The Company thanks Mr. Carleton for his service and contributions to the Board. “Richard has been a great addition to the board, and we thank him for his tremendous insights and appreciate everything he has done for the Company,” said Fred Niehaus, Chairman of the Board of Directors.

“Tyler and Sean bring the type of experience that strengthens our ability to execute on the opportunity before us,” continued Mr. Niehaus. “Tyler’s background at the intersection of cannabis regulation and federal policy is directly relevant as the regulatory environment continues to evolve, and Sean’s experience advising governments and major organizations on strategic communications and public affairs adds an important dimension to our Board as the Company grows its platform and expands its market presence. We are pleased to welcome them both.”

Mr. Klimas is the founder of Leaf Street Strategies, a Washington, DC-based regulatory affairs and consulting firm specializing in cannabis and hemp policy, regulatory strategy and market development. Prior to founding Leaf Street Strategies, Mr. Klimas was the first Executive Director of the Nevada Cannabis Compliance Board, where he designed and led the agency responsible for regulating Nevada’s billion dollar cannabis and adult cannabis markets. Mr. Klimas is the co-founder and former president of the Cannabis Regulators Association (CANNRA), a non-profit association of cannabis regulators from more than 45 US states and territories, Canada and the Netherlands. He previously served as Nevada’s top federal lobbyist under Governors Brian Sandoval and Steve Sisolak.

“Safe Harbor has played a key role in building the infrastructure that allows cannabis businesses to operate with financial legitimacy,” said Mr. Klimas. “I look forward to contributing to the Company’s continued growth at a time when the regulatory landscape is changing in ways that create significant opportunities for the platform that Safe Harbor has built.”

Mr. Tonner has served as managing partner of Fulcrum Group since December 2017 and is a seasoned strategic communications and public affairs leader with experience advising governments and corporations globally. He has served in senior positions for Presidents, Premiers and Governors, and has extensive experience in high-profile political campaigns, global brand reputation management and leadership roles in Colorado business and civic organizations. Mr. Tonner is a veteran of the US Army and was awarded the Army Commendation Medal for Valor during Operation Desert Storm.

“Safe Harbor is building something truly distinct in a rapidly maturing market,” Mr. Tonner said. “I am excited to join the Board and support the leadership of the Company as its platform grows and its position as the financial partner of choice for the cannabis industry continues.”

For more information:
Safe Harbor Financial
shfinancial.org

Related Topics:
Continue Reading

Cannabis News

Massachusetts CCC pauses license applications

Published

7 hours ago

on

June 17, 2026

By











The Cannabis Control Commission, the government body that oversees the marijuana business in the state of Massachusetts (USA), has decided to temporarily stop accepting new license applications for growing marijuana, both indoors and outdoors. This hiatus officially began on June 16, 2026.

Anyone planning to apply for a new marijuana cultivation license after June 16, 2026 will not be able to do so while this suspension is in effect. The Commission will not accept such requests during this period.

There are two groups that can continue normally. First, anyone who submitted an application before June 16, 2026, will continue to review and process applications as usual. Second, applicants for specific programs designed to help communities historically affected by drug laws, known as the Social Equity Program and the Economic Empowerment Program, are exempt from this suspension if they apply for a smaller-scale “Microenterprise” license.

The suspension will be in effect for 120 days from June 16, 2026, which is currently scheduled to be lifted around mid-October 2026. However, the Commission has the power to terminate earlier or extend further, depending on market conditions.

Source: Massachusetts Cannabis Control Commission










Continue Reading

Cannabis News

Federal Marijuana Rescheduling ‘Does Not Appear To Apply’ To Washington Businesses, State Officials Say

Published

7 hours ago

on

June 17, 2026

By

Marijuana regulators in Washington say the Trump administration’s move to re-regulate cannabis at the federal level “doesn’t appear to apply” to the state’s businesses.

US Department of Justice in April He issued an order that immediately reclassified the state’s licensed medical cannabisas well as marijuana products approved by the Food and Drug Administration (FDA) under Schedule I through Schedule III of the Controlled Substances Act (CSA). A trial scheduled for this month will take place consider marijuana III.

“Washington does not issue licenses to producers, processors or retailers of medical cannabis,” the state’s Liquor and Cannabis Board (LCB) said in guidelines released Tuesday. “Instead, Washington has a single recreational market and within that market producers/processors can manufacture (DOH) compliant products, and certain retailers can sell DOH-compliant products to adult patients and all designated providers.”

“Therefore, Washington cannabis licensees do not appear to qualify as ‘state medical marijuana licensees’ and therefore may not be eligible for registration under the final Rule,” the agency said, referring to the Drug Enforcement Administration (DEA). Registration process for legal marijuana businesses in the state to take advantage of the federal benefits that come with the reform.

That said, the LCB “does not take a position if licensees decide to apply for federal registration,” the guidance continues. “If a licensee is seeking federal registration, we would be interested in learning about their experience and federal decisions.”

However, “based on our analysis, the federal reorganization in its current form does not appear to apply to cannabis licensees in Washington, primarily because of the legal framework governing recreational cannabis,” the LCB said.

The agency emphasized, however, that while it has consulted with the Cannabis Regulatory Association, the National Governors Association and industry stakeholders, its current opinion does not represent Washington’s formal opinion and “may not be our final interpretation as information is evolving and the decision may not rest with the state.”

“We await additional guidance from the federal agencies involved, new or updated federal agency processes and/or other federal procedures,” he said. he saidreferring to the next administrative hearing and Ongoing litigation calls into question the rescheduling of cannabis.

“The LCB recognizes that there are many cannabis growers, processors, and retailers actively involved in the production and sale of medical cannabis in Washington. These businesses may or may not be eligible to use the 280e tax deduction, and may also register with the DEA III. Ultimately, they have no input into whether their licensees meet the criteria for “state medical marijuana licensees,” as that determination can be made unilaterally by the DOJ within the meaning of the Final Rule. to reasonably interpret and determine that Washington cannabis licensees qualify as “state medical marijuana licensees.”

The US Treasury and Internal Revenue Service (IRS) said they plan to issued new tax guidelines for the marijuana industry after reprogramming. The reform will benefit state-licensed marijuana businesses by allowing them to take federal tax deductions that are currently prohibited under IRS Code Section III, known as Section 280E.

In California, regulators recently approved emergency rule changes to the state’s marijuana licensing process. to make it easier for companies to receive benefits In line with the Trump administration’s latest move to federally regulate medical cannabis.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Continue Reading

Cannabis News

How New Zealand showed up in London’s cannabis industry

Published

1 day ago

on

June 16, 2026

By

The medical cannabis market is expected to grow from $47 billion to $149 billion by 2031, and New Zealand has a real role to play in that story. And thanks in large part to New Zealand Trade and Enterprise (NZTE), the government’s international business development agency, Puro is starting to play.

At Cannabis Europa 2026 London, NZTE hosted an evening event at the City Arts Bar with Puro, New Zealand companies Bluelab, Rua Bioscience and CannFX. Puro called it The NZ Room.

Beyond all things Kiwiana – including Puro brand kiwifruit, Kiwi’d – the room was filled with some pretty amazing people: Ivy League scientists, company founders, patients, advocates, industry players, government officials, Maori tribal leaders and a tough Scotsman. All in the same space with the same true passion for where this industry is going.

It was one of those rooms where conversations went well when they had to end. That’s usually a sign of something well done.

Made possible by NZTE
For Puro, the NZTE relationship has been formative. With ongoing support, Puro has entered the Australian market with 47 unique product SKUs and signed a £7 million supply agreement with UK distributor IPS Pharma.

NZTE understands the potential of the New Zealand cannabis industry. The willingness to support this nascent industry and put New Zealand in the spotlight at events like Cannabis Europa is very significant. New Zealand is a small country and the country’s credibility in international markets is built from relationship to relationship, room by room. NZTE helps build those rooms.

© Cigar

what’s next
For the first time, patients in the UK have access to medicinal cannabis grown in New Zealand. That’s the direct result of years of work by Puro’s team, but it’s not worth much if you can’t connect with buyers globally. Creating international relationships that events like Cannabis Europa make this possible.

“We are grateful for the extensive support from the New Zealand Government that drives our progress, including the Ministry of Primary Industries’ support for our genetic breeding, product innovation and market access goals. This collective effort from agencies such as the Ministry of Business, Innovation and Employment, NZTE and the New Zealand Export Credit Bureau ensures that Mail that started in London will continue to grow in Puro’s international goals,” he said. a statement

For more information:
clean
www.puro.co.nz

Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media